A newly developed experimental drug could help mitigate some of the dangerous side effects of promising diabetes drugs. Early animal trials have shown that this new combination of the raptosis is both safe and effective in helping to regulate blood sugar levels in patients with type 2 diabetes.
Rosiglitazone was first approved by the FDA for human use in 1999. It is undoubtedly effective as a treatment for people with type 2 diabetes, but as more and more reports of a range of adverse reactions are reported, people are quickly starting to worry. Heart failure, osteoporosis, weight gain, and fluid retention are all studied side effects associated with rosigretone.
By 2010, it was clear that roglitazone was having a problem. Drugmaker GlaxoSmithKline is facing a series of civil lawsuits that were eventually found guilty by the U.S. government of concealing research data that suggested the drug could increase the risk of heart attack. Since then, the drug has been removed from several international markets, but it can still be used in the United States.
A recently published study from the Yale School of Public Health is the largest systematic review to date to investigate the link between roglitazone and heart problems. The study confirms that the drug does increase a person’s risk of cardiovascular problems.
“Roglitazone has long been used to treat type 2 diabetes and insulin resistance,” explained Da Young Oh, from the University of Texas Southwestern Medical Center. This medicine is very good — very effective. At the same time, however, there are still serious side effects, including weight gain, fluid retention, etc. “
The new study combines roglitazone with a new experimental small molecule compound A for testing. Activate this receptor in fat cells and some immune cells, which can improve insulin sensitivity and reduce inflammation. Omega-3 fatty acids in fish oil are a natural GPR120 activator.
Animal tests have shown that roglitazone and compound A work together to reduce insulin sensitivity in diabetic mouse models. Most importantly, this combination of treatments allows low doses of roglitazone to produce results similar to those seen in higher doses with more problems.
“The ultra-low dosewed we used in this study did not show any side effects in mouse models — no weight gain, no fluid retention,” da Young Oh said. “Hopefully we can use roglitazone in a lower dose to treat people with type 2 diabetes in a more effective way without side effects.” “
At this stage, animal studies have not specifically demonstrated that this combination of therapy directly alleviates osteoporosis and heart problems that occur after humans take roglitazone. While the study does assume that lower doses of roglitazone may avoid higher doses of dangerous adverse reactions, this needs to be validated in future studies.
Compound A was developed by Merck, one of the world’s largest pharmaceutical companies. At this stage, it is still an early research drug, so we still have a long way to go before we see this new roglitazone combination therapy being used clinically.
The new study is published in the journal Cell Metabolism.